D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)
Acquired by
EURAZEO
D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquired by EURAZEO
Target
D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)
Acquirer
EURAZEO
Context
Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs.
The transaction values D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) at an EV/Revenue multiple of LOGIN.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Headquartered in the Netherlands, D.O.R.C. is a global leader in ophthalmic surgery equipment. It specializes in the "posterior segment" of the eye (vitreoretinal surgery). Its flagship product, the EVA Nexus platform, is a dual-function system used for both cataract and retina surgeries, highly regarded by surgeons for its precision.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 08/2023 | CARL ZEISS MEDITEC | D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) | NETHERLANDS | Medical Devices | Eurazeo has completed the sale of D.O.R.C. to Carl Zeiss Meditec AG. This transaction marks the successful conclusion of a four-year transformation under Eurazeo's ownership, during which D.O.R.C. evolved from a European champion into a global platform. The strategic rationale for Zeiss is to create a comprehensive "end-to-end" offering for ophthalmologists. By integrating D.O.R.C.'s leading vitreoretinal surgical systems with Zeiss's existing portfolio of diagnostics, microscopes, and digital workflows, the combined entity becomes a one-stop-shop for eye care providers. The deal also unlocks significant cross-selling opportunities, leveraging Zeiss's massive global distribution network to accelerate the adoption of D.O.R.C.'s products in under-penetrated markets. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.